Login to Your Account



Small Rebound for Ariad Stock on Positive CHMP Vote for Iclusig

By Jennifer Boggs
Managing Editor

Monday, November 25, 2013
Shares of Ariad Pharmaceuticals Inc. gained 35.5 percent Friday after the European Committee for Medicinal Products for Human Use (CHMP) recommended that leukemia drug Iclusig (ponatinib) remain on the market in Europe.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription